Brookline Capital Management Comments on QNCX Q3 Earnings

Quince Therapeutics, Inc. (NASDAQ:QNCX - Free Report) - Brookline Capital Management cut their Q3 2025 EPS estimates for Quince Therapeutics in a research report issued on Wednesday, July 16th. Brookline Capital Management analyst K. Raja now anticipates that the company will earn ($0.25) per share for the quarter, down from their previous estimate of ($0.24). The consensus estimate for Quince Therapeutics' current full-year earnings is ($1.21) per share. Brookline Capital Management also issued estimates for Quince Therapeutics' Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.13) EPS, FY2026 earnings at ($0.85) EPS, FY2027 earnings at ($0.51) EPS and FY2029 earnings at $0.48 EPS.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.10).

A number of other equities research analysts also recently issued reports on QNCX. Oppenheimer began coverage on shares of Quince Therapeutics in a report on Monday, March 24th. They issued an "outperform" rating and a $10.00 price target on the stock. D. Boral Capital reissued a "buy" rating and issued a $4.00 price target on shares of Quince Therapeutics in a report on Thursday. Finally, Wall Street Zen downgraded shares of Quince Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. One analyst has rated the stock with a sell rating, five have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $8.00.

Quince Therapeutics Price Performance

NASDAQ QNCX opened at $1.89 on Monday. Quince Therapeutics has a 52 week low of $0.51 and a 52 week high of $2.45. The company has a market cap of $85.94 million, a PE ratio of -1.36 and a beta of 0.96. The company has a quick ratio of 4.05, a current ratio of 4.05 and a debt-to-equity ratio of 0.82. The firm's 50-day simple moving average is $1.33 and its two-hundred day simple moving average is $1.36.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Ieq Capital LLC purchased a new stake in Quince Therapeutics in the first quarter worth $1,073,000. Geode Capital Management LLC lifted its position in Quince Therapeutics by 10.9% during the fourth quarter. Geode Capital Management LLC now owns 375,932 shares of the company's stock valued at $703,000 after buying an additional 36,807 shares during the period. Shay Capital LLC lifted its position in Quince Therapeutics by 60.8% during the fourth quarter. Shay Capital LLC now owns 276,799 shares of the company's stock valued at $518,000 after buying an additional 104,616 shares during the period. Intellectus Partners LLC purchased a new position in Quince Therapeutics during the first quarter valued at $71,000. Finally, Northern Trust Corp lifted its position in Quince Therapeutics by 48.5% during the fourth quarter. Northern Trust Corp now owns 50,524 shares of the company's stock valued at $94,000 after buying an additional 16,501 shares during the period. Institutional investors own 30.75% of the company's stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.